Published in Cell Death Dis on March 20, 2014
Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer (2015) 0.77
From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitor. Cell Death Dis (2016) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res (2010) 12.96
HDAC6 is a microtubule-associated deacetylase. Nature (2002) 12.76
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51
Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc (2006) 8.42
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res (2007) 4.91
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science (1983) 3.88
Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A (2003) 3.86
Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol (2006) 3.63
Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 3.49
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest (2009) 3.14
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst (1994) 2.92
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A (2010) 2.41
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther (2006) 2.40
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett (2008) 2.33
Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem (2005) 2.06
Dynamics of microtubule depolymerization in monocytes. J Cell Biol (1986) 2.01
Target-based drug discovery: is something wrong? Drug Discov Today (2005) 1.88
PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell (2009) 1.65
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res (2005) 1.64
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets (2006) 1.35
Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer (1996) 1.33
Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res (1999) 1.31
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res (2007) 1.27
Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther (2006) 1.27
BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem (2004) 1.25
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12
E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes Dev (2012) 1.12
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res (2007) 1.08
Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv Pharmacol (1990) 1.02
Multidrug resistance in non-small-cell lung cancer. Ann Oncol (1999) 1.01
Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene (2001) 1.01
The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci (2009) 0.96
p53 target gene AEN is a nuclear exonuclease required for p53-dependent apoptosis. Oncogene (2008) 0.94
Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs (2000) 0.93
P-glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone]. J Pharmacol Exp Ther (2005) 0.86
Interaction of combinations of drugs, chemosensitizers, and peptides with the P-glycoprotein multidrug transporter. Biochem Pharmacol (1997) 0.86
JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells. Cell Mol Life Sci (2005) 0.86
Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. J Pharmacol Exp Ther (2009) 0.84
Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS One (2011) 0.83
Anti-tumor selectivity of a novel tubulin and HSP90 dual-targeting inhibitor in non-small cell lung cancer models. Biochem Pharmacol (2013) 0.81
Proteome interrogation using nanoprobes to identify targets of a cancer-killing molecule. J Am Chem Soc (2011) 0.77
Discovery of small molecules that target autophagy for cancer treatment. Curr Med Chem (2011) 0.76